May 6, 2014 — Devicor Medical Products Inc. acquired the HydroMARK breast biopsy marker portfolio and related assets from Biopsy Sciences LLC.
HydroMARK was developed by John Fisher, M.D., an interventional radiologist with extensive experience in breast imaging and breast biopsy. Fisher and his team developed HydroMARK to provide physicians with a long-term ultrasound visible breast biopsy-marking alternative. Long-term ultrasound visibility provides physicians with the option to eliminate a procedural step that can reduce the anxiety and pain of traditional breast cancer treatment.
The acquisition of HydroMARK is the latest in a series of product additions by Devicor, including the addition of the Mammotome MammoTest stereotactic table, and a new distribution agreement with Faxitron on their CoreVision, core specimen radiography system. These complement recent internally developed products, Mammotome revolve and Mammotome elite. HydroMARK is currently available in most of North and South America, Europe and parts of Asia.
For more information: www.gtcr.com, www.devicormedical.com, www.mammotome.com.
April 30, 2024 
